Acalabrutinib shows promise in Waldenström’s macroglobulinaemia Standard post … that has come back (relapsed) or not responded (refractory) to previous treatment, or for first-line …
Brentuximab vedotin recommended by NICE for advanced T-cell skin lymphomas Standard post … advanced T-cell skin lymphomas who have not responded ( refractory ) or whose lymphoma has come back ( relapsed ) …
People with diffuse large B-cell lymphoma or follicular lymphoma and limited treatment options could benefit from new drug Standard post … follicular lymphoma that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment. …
EBV: A phase 2 trial of tabelecleucel in people with Epstein-Barr virus associated diseases Trial … newly diagnosed or has not responded to previous treatment(refractory) or has come back after treatment (relapsed). …
Acalabrutinib approved for NHS treatment of CLL in England and Wales Standard post … with CLL that has come back (relapsed) or not responded (refractory) after previous treatment. Acalabrutinib is a type …
Ibrutinib plus rituximab effective for younger people with previously untreated CLL Standard post … medicines for people with CLL that has relapsed or is refractory to first-line treatment. In this trial, people …
Another CAR T-cell therapy approved in Scotland Standard post … large B cell lymphoma (PMBL) that has not responded ( refractory ) or has come back ( relapsed ) after at least two …
New information on stem cell transplants Standard post … treatment your lymphoma hasn’t responded to treatment (refractory lymphoma) your lymphoma has relapsed after …
Brentuximab vedotin Standard post … previous treatment people with some types of relapsed or refractory T-cell skin lymphoma who have relapsed or has not …
RAINBOW: a randomised, phase 2/3 trial comparing ibrutinib plus rituximab with standard treatment in people with Waldenström’s macroglobulinaemia Trial … that has come back (relapsed) or not responded (refractory) to initial treatment. DRC is standard treatment …